Talia Velasco-Hernandez

List of Publications by Year
in descending order

22	832	759055 12	794469 19
papers	citations	h-index	g-index

24	24	24	1813
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Distinct roles for PARP-1 and PARP-2 in c-Mycâ€“driven B-cell lymphoma in mice. Blood, 2022, 139, 228-239.	0.6	16
2	A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL. Molecular Therapy, 2022, 30, 550-563.	3.7	21
3	The insecticides permethrin and chlorpyrifos show limited genotoxicity and no leukemogenic potential in human and murine hematopoietic stem progenitor cells. Haematologica, 2022, 107, 544-549.	1.7	3
4	A somatic mutation in moesin drives progression into acute myeloid leukemia. Science Advances, 2022, 8, eabm9987.	4.7	2
5	Engraftment characterization of risk-stratified AML patients in NSGS mice. Blood Advances, 2021, 5, 4842-4854.	2.5	5
6	Design and in Vitro Evaluation of a CAR-T Prototype (ARI-0003) Targeting CD123 for Acute Myeloid Leukemia. Blood, 2021, 138, 4799-4799.	0.6	0
7	Efficient elimination of primary B-ALL cells in vitro and in vivo using a novel 4-1BB-based CAR targeting a membrane-distal CD22 epitope. , 2020, 8, e000896.		7
8	41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo. , 2020, 8, e000845.		37
9	Metabolic and Innate Immune Cues Merge into a Specific Inflammatory Response via the UPR. Cell, 2019, 177, 1201-1216.e19.	13.5	100
10	Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia. Blood, 2019, 133, 2291-2304.	0.6	87
11	CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity. Leukemia, 2019, 33, 2090-2125.	3.3	30
12	Hif-1Î± Deletion May Lead to Adverse Treatment Effect in a Mouse Model ofÂMLL-AF9-Driven AML. Stem Cell Reports, 2019, 12, 112-121.	2.3	10
13	The â€œNeverâ€Endingâ€•Mouse Models for MLLâ€Rearranged Acute Leukemia Are Still Teaching Us. HemaSphere, 2018, 2, e57.	1.2	8
14	Induction of the 5S RNPâ€“Mdm2â€“p53 ribosomal stress pathway delays the initiation but fails to eradicate established murine acute myeloid leukemia. Leukemia, 2017, 31, 213-221.	3.3	5
15	Targeting hypoxia pathway in a model of acute myeloid leukemia. Experimental Hematology, 2017, 53, S61.	0.2	0
16	Agonistic targeting of TLR1/TLR2 induces p38 MAPK-dependent apoptosis and NFÎºB-dependent differentiation of AML cells. Blood Advances, 2017, 1, 2046-2057.	2.5	35
17	Potential Pitfalls of the Mx1-Cre System: Implications for Experimental Modeling of Normal and Malignant Hematopoiesis. Stem Cell Reports, 2016, 7, 11-18.	2.3	53
18	Deregulation of Genes Related to Iron and Mitochondrial Metabolism in Refractory Anemia with Ring Sideroblasts. PLoS ONE, 2015, 10, e0126555.	1.1	21

#	Article	IF	Citations
19	Loss of HIF-1Î± accelerates murine FLT-3ITD-induced myeloproliferative neoplasia. Leukemia, 2015, 29, 2366-2374.	3.3	16
20	HIF-1Î± can act as a tumor suppressor gene in murine acute myeloid leukemia. Blood, 2014, 124, 3597-3607.	0.6	95
21	p53 restoration kills primitive leukemia cells in vivo and increases survival of leukemic mice. Cell Cycle, 2013, 12, 122-132.	1.3	16
22	Functional Inactivation of Endogenous MDM2 and CHIP by HSP90 Causes Aberrant Stabilization of Mutant p53 in Human Cancer Cells. Molecular Cancer Research, 2011, 9, 577-588.	1.5	238